Background {#Sec1}
==========

Uganda remains a malaria high burden country, with eastern Uganda experiencing perennial high malaria transmission with \> 100 infective bites per person per year \[[@CR1], [@CR2]\]. In endemic areas where mothers have acquired considerable immunity to malaria, infection with *Plasmodium falciparum* during pregnancy does not always cause symptomatic illness \[[@CR3]\]. Congenital malaria results from transplacental transmission of malaria parasites from the mother to the baby in utero or during delivery. Its diagnosis is based upon detection of asexual forms of malaria parasites on a blood smear of the peripheral blood of the newborn, or later if there is no possibility of postpartum infection through infective mosquito bites \[[@CR4]\]. However, these definitions are not precise if time is not tagged to them to enable differentiate congenital from neonatal malaria. Furthermore, precision of definitions would be achieved by using temporal relationship with PCR testing for malaria in the mother and their neonate. The reported incidence of congenital malaria in endemic regions varies widely from 0 to 37% \[[@CR5]--[@CR7]\]. It is widely believed that the placenta acts as an effective barrier preventing transfer of malaria parasites. However, even in the absence of congenital malaria, placental malaria significantly increase the risk of perinatal morbidity and mortality including low birth weight, intrauterine growth restriction, preterm labour and intrauterine fetal death \[[@CR8]\]. Malaria in pregnancy is estimated to account for 100,000 neonatal deaths annually \[[@CR3]\]. Maternal malaria can be prevented during pregnancy with intermittent presumptive treatment of malaria in pregnancy (IPTp) using sulfadoxine--pyrimethamine, and can reduce neonatal mortality by up to 61% \[[@CR9]\].

It is also possible that maternal immunity to malaria may confer protection to the fetus through transmission of immunoglobulin G antibodies (IgG) against malaria \[[@CR10]\]. The presence of fetal haemoglobin (HbF) in the neonate also prevents high parasitaemia \[[@CR11]\]. However as maternal IgG and HbF in infants diminish with age, the infant's susceptibility to *P. falciparum* increases. It is possible that this passive immunity may delay the onset or modify severity of symptoms by up to 6 weeks after birth making it hard to differentiate between congenital and neonatal malaria \[[@CR12]\]. To maximize the chances of early detection of congenital malaria, neonates born to mothers with malaria in the last 7 days before delivery should be investigated with a blood film for malaria parasites irrespective of the clinical picture and weekly thereafter for the first month.

In the eastern region of Uganda, despite perennial malaria transmission, NCM is a rarely reported condition presumably because of low index of suspicion among clinicians, and greater emphasis on the diagnosis and treatment of neonatal sepsis (NS). Although it is recommended that neonates be routinely tested if mother was known to suffer from malaria in the 7 days before delivery, in practice it is often not routine to test neonates for malaria and, therefore, many cases may be missed. In neonates, the historical and most common symptom of malaria is fever \[[@CR13]\]. Other symptoms and signs differ from those in older children with malaria, the clinical features of neonatal and congenital malaria overlap with sepsis syndromes \[[@CR14]\]. Other symptoms can include anaemia, jaundice, diarrhoea, vomiting, lethargy, convulsions, irritability, tachypnoea, respiratory distress, hepatosplenomegaly \[[@CR14]\]. Clinical descriptions and outcomes of NCM remain poorly documented even in malaria endemic areas where descriptions in infants, older children and adults have over the times progressed. More comprehensive descriptions inclusive of NCM are needed, especially from areas with intense transmission, and serially over time.

At Mbale Regional Referral Hospital IPTp is routinely administered to pregnant mothers, however, not all pregnant mothers in the region served by this hospital attend antenatal care. At the hospital NNU there are estimated 200 admissions per month. During the study period June--December 2017 routine blood slides for malaria for all neonates admitted with fever had been introduced. This report is on four cases of NCM that highlight the presenting clinical features and their outcomes in a perennially malaria high transmission area in eastern Uganda. This has shown that malaria is a potentially missed diagnosis or co-morbidity in neonatal illnesses in malaria endemic areas.

Case presentation {#Sec2}
=================

In this study congenital was differentiated from neonatal malaria based on the time of presentation from birth. Congenital malaria, as was previously defined, was used to classify cases 1 and 2 (Table [1](#Tab1){ref-type="table"}). However, this description modified the definition for neonatal malaria that was applied by Runsewe-Abiodun et al. in Nigeria \[[@CR15]\]. Therefore, for cases 3 and 4 (Table [1](#Tab1){ref-type="table"}), this study considered symptoms attributable to malaria with evidence of ring forms of malaria parasite in the erythrocyte of an infant within the 8th--28th days of life. The maternal age was similar across all the 4 cases, range 24--28 years. The two neonatal malaria cases (3 and 4) were born to primigravidae who had no recent history of fever in the 14 days to delivery. Three of the cases presented with fever or history of fever, while one of the congenital cases was hypothermic (34.8 °C), possibly due to the concurrent prematurity. This same infant was also born to an HIV+ mother. Whereas there are many risk factors for preterm deliveries, it is possible that in this mother either the HIV \[[@CR16]\], or antiretroviral drugs \[[@CR17]\], may have contributed to both prematurity and susceptibility to malaria in this baby. The other congenital malaria case had clinical jaundice and pyogenic meningitis. The jaundice in this case 1 was attributed to a number of possible factors including neonatal jaundice, sepsis, malaria or a combination of these. Poor breastfeeding was noted in both congenital cases. All of the cases of NCM were treated with intravenous artesunate 4 mg/kg at 0, 12, 24 h then daily for 7 days. Since sepsis could not be excluded due to lack of laboratory investigative capacity, the admitting clinicians also instituted a course of broad-spectrum antibiotics empirically to cover against possible bacterial infections. All cases recovered and were discharged alive.Table 1Summary of admission characteristics and outcomes of neonatal and congenital malariaVariableCongenital malariaNeonatal malariaCase 1Case 2Case 3Case 4Mother Age (years)28242426 HIV statusNegativePositiveNegativeNegative Parity2 + 13 + 01 + 01 + 0 Fever within 14 days of deliveryYesYesNoNoNeonate Age (days)211416 SexMFMF Birth weight (kg)2.71.73.52.8 Admission weight (kg)2.41.73.92.5Symptoms FeverYesNoYesYes Duration of fever (days)1032 Fast breathingYesNoNoYes BreastfeedingNoNoYesYes Poor feedingYesYesNoNoSigns Temperature (°C)40.134.836.139.1 JaundiceYesNoNoNo PallorYesNoNoNo Respiratory rate (breath/m)104Not takenNot taken72 Heart rate (BPM)225108166113 SP0~2~ (%)96799668 HepatomegalyNoNoNoNo SplenomegalyNoNoNoNo TachycardiaYesNoYesNoLaboratory CSF  Proteins (g/L)0.3NoNo\< 0.1  Sugar (mmol/L)8.12NoNo10.08  WBC75 × 10^6^/LNoNo\< 5 × 10^6^/L Malaria  Blood slidePositivePositivePositivePositive Treatment  Antibiotics^a^Cefotaxime/GentaAmp/GentaAmp/GentaAmp/Genta  Anti-malarialArtesunateArtesunateArtesunateArtesunate  Blood transfusionNoNoNoNo  OxygenNoYesNoYes Outcome  At dischargeAliveAliveAliveAlive*Ampi/Genta* ampicillin and gentamycin, *BPM* beats per minute, *°C* degree celsius, *g/L* grams per litre, *kg* kilogram, *L* litre, *mmol* millimole, *WBC* white blood cell^a^Empirical treatment

Discussion and conclusions {#Sec3}
==========================

In this case series, a description is made of both congenital and neonatal malaria in a setting that introduced routine neonatal malaria testing in a malaria endemic area. This case series shows that NCM malaria is more common than previously thought \[[@CR18]\]. It is also a reminder that NCM still exists despite IPTp and other malaria preventive measures, and its diagnosis may be missed especially when malaria screening measures are not put in place in NNUs in malaria endemic areas. Other reports suggest that the incidence of NCM may be increasing. Proper descriptions of NCM are important to ensure more comprehensive understanding of the clinical spectrum and outcomes of malaria in neonates. Malaria endemicity has been suggested to play a role in the prevalence of NCM. There are reports suggesting in hyperendemic areas the prevalence of NCM is higher \[[@CR5], [@CR15]\], while others are contrary \[[@CR7]\]. It is however, plausible epidemiologically that in settings of intense perennial transmission the mothers have developed herd immunity, their newborn babies have protective antibodies to the disease, and therefore the prevalence is negligible \[[@CR10]\]. Some underlying factors may be responsible for the equipoise observed in this case series. For instance, primigravidae are known to have a high risk for malaria compared to multigravidae \[[@CR19]\]. In addition, the role of maternal malaria in congenital malaria infections has been traced to infections in the third trimester \[[@CR15]\]. It is also possible that co-morbidity that damages the placenta in utero may contribute to the risk of the congenital malaria. HIV co-infected pregnant women may have impaired antibody response and have been shown to have a significantly increased risk of placental malaria \[[@CR20]\]. This is consistent with some reports suggesting that HIV increases the chances of vertical transmission of malaria \[[@CR16], [@CR20]\]. Maternal low age has been reported to influence congenital malaria \[[@CR19]\]. In this series, all the mothers were within the same age range, but their parities differed.

Although rapid malaria tests have been used for the diagnosis of NCM, the gold standard for the diagnosis of NCM is the detection of parasites in the Giemsa-stained peripheral blood smear \[[@CR21]\]. The Mbale RRH-NNU recently introduced routine testing for malaria using blood smears in neonates reporting with signs of sepsis. Consequently, all cases identified with NCM were managed with good outcomes.

On treatment, amodiaquine, chloroquine and sulfadoxine--pyrimethamine have all been successfully used in Nigeria to treat neonates with malaria \[[@CR22]\]. Although artemisinin-based combination therapy (ACT) is the recommended treatment for uncomplicated malaria in infants, the neonates have been largely excluded from ACT clinical trials. There are, therefore, limited data available on the use of ACT in neonates and many of them carry label restrictions for neonates \[[@CR23]\]. For infants weighing less than 5 kg with uncomplicated *P. falciparum*, the World Health Organization (WHO) recommends treatment with ACT at the same mg/kg body weight dose as for children weighing 5 kg. The WHO acknowledges too that most anti-malarials lack infant formulations, which can lead to either under or over dosing. In addition, infants can deteriorate rapidly therefore there should be a low threshold for parenteral treatment. Many anti-malarials are frequently used off-label based on the dosing schedule for older children \[[@CR24]\], but have not reported evidence of serious toxicity \[[@CR23]\].

Due to the physiological immaturity and rapid changes that occur in neonates, the pharmacokinetic and dynamic (PK/PD) profiles of anti-malarial drugs are likely to be different to older children. Slow gastric emptying, villous formation and intestinal motor activity, which do not mature until week 20 of life, affect the enteral absorption of most medications \[[@CR25]\]. Parenteral treatment is preferable for neonates and young infants. Differentiating congenital from neonatal malaria based on temporal relationship to birth may be strengthened by inclusion of DNA PCR for both the mother and her newborn to determine the source of the infection. But in resource limited areas there are no routine DNA PRC testing services due to prohibitive capital, running and maintenance costs, except in research settings. The temporal characteristic would help interpret the role of physiological immaturity in neonates for future PK/PD studies on anti-malarial drugs in this age group, and how these determine treatment outcomes.

Limitations {#Sec4}
===========

This is only a case series with case definitions based on temporal relationships from birth to case presentation. A larger study with capacity to conduct molecular, parasite count and PK/PD testing, and long term follow up would help better refine definitions, outcomes and interpretation of these findings. Nonetheless, this report has been able to demonstrate that NCM still exists. The definitions used have set pace in appropriate description of the spectrum of disease in this age group and will strengthen interpretation of anti-malarial PK/PD studies in this population in relation to the physiological immaturity.

Conclusion {#Sec5}
==========

In summary, NCM is an important diagnosis to consider in any newborn with clinical features of NS to a mother in a malaria-endemic area. It is possible that in the absence of routine malaria testing many neonates are dying before malaria is diagnosed. In areas with malaria endemicity the burden of NCM may be underestimated. Malaria test should be incorporated as routine test in neonates with suspected sepsis so as not to miss NCM. Early and correct diagnosis of NCM is crucial as infants are at increased risk of rapid disease progression, severe malaria and death. Additional efforts are needed to establish the safety profile and efficacy of ACT in neonates to guide the development of evidence-based treatment guidelines for NCM. Furthermore, for pregnant mothers who test malaria positive in their late gestational period weekly malaria testing of their babies as follow up mechanism for surveillance of NCM should be done.

EIEE, KN, JI, LA and KB---collected the data and participated in writing the manuscript; P-OO---conceived the idea and wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgements {#FPar1}
================

The authors acknowledge Mbale Regional Referral Hospital, Mbale Clinical Research Institute and all staff at the Mbale RRH-NNU for their various contributions to this work.

Competing interests {#FPar2}
===================

The authors declare that they have no competing interests.

Availability of data and materials {#FPar3}
==================================

The study data is available on personal request to the corresponding author.

Consent to publish {#FPar4}
==================

The Mbale Clinical Research Institute (MCRI, <http://www.mcri.ac.ug>), a research entity affiliated to the Uganda National Health Research Organization (UNHRO), permits the publication of this manuscript.

Ethics approval and consent to participate {#FPar6}
==========================================

The Mbale Regional Referral Hospital Research & Ethics Committee (MRRH-REC) approved the study and local permission to conduct the study was obtained from Mbale Regional Referral Hospital.

This study was conducted within the provisions of ethical standards in Uganda.

Funding {#FPar7}
=======

This study was not funded.

Publisher's Note {#FPar8}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
